{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:12:53Z","timestamp":1790521973571,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.critrevonc.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T13:26:03Z","timestamp":1542288363000},"page":"99-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Advanced stage melanoma therapies: Detailing the present and exploring the future"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-2650","authenticated-orcid":false,"given":"Chelsea","family":"Luther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-6187","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-6824","authenticated-orcid":false,"given":"Mohammed","family":"Milhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1A","key":"10.1016\/j.critrevonc.2018.11.002_bib0005","first-page":"56","article-title":"The revival of CpG oligonucleotide-based cancer immunotherapies","volume":"22","author":"Adamus","year":"2018","journal-title":"Contemp. Oncol. (Pozn.)"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ijc.26320","article-title":"Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo","volume":"131","author":"Alcazar","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2018.11.002_bib0015","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2018.11.002_bib0020","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0025","series-title":"Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination With KEYTRUDA\u00ae (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma [press release]","author":"Anon","year":"2018"},{"issue":"26","key":"10.1016\/j.critrevonc.2018.11.002_bib0030","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.002_bib0035","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.11.002_bib0040","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0045","series-title":"SITC 2016: Phase I\/II Data Combining Urelumab With Nivolumab Suggest Increased Antitumor Effect in Patients With Melanoma","author":"ASCO Post","year":"2016"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.11.002_bib0050","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2016.34.15_suppl.3020","article-title":"Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine\/nab-paclitaxel for the treatment of metastatic pancreas cancer: interim analysis [abstract]","volume":"34","author":"Bahary","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0055","article-title":"Abstract CT137: combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma [abstract]","volume":"75","author":"Bajor","year":"2015","journal-title":"Cancer Res."},{"issue":"36","key":"10.1016\/j.critrevonc.2018.11.002_bib0060","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2018.11.002_bib0065","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1200\/JCO.2005.08.036","article-title":"Raf: a strategic target for therapeutic development against cancer","volume":"23","author":"Beeram","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2018.11.002_bib0070","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0080","series-title":"NewLink Genetics, Ames, IA. Indoximod Modulates AhR-Driven Transcription of Genes That Control Immune Function AACR","author":"Brincks","year":"2018"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2018.11.002_bib0090","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/1078-0432.CCR-15-2944","article-title":"Ipilimumab combined with nivolumab: a standard of care for the treatment of advanced melanoma?","volume":"22","author":"Carlino","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0095","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1200\/JCO.2017.35.15_suppl.9545","article-title":"KEYNOTE-029: efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma [abstract]","volume":"35","author":"Carlino","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2018.11.002_bib0100","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.canlet.2017.01.040","article-title":"Metronomic chemotherapy and immunotherapy in cancer treatment","volume":"400","author":"Chen","year":"2017","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.002_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010436","article-title":"Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation","volume":"5","author":"Cohen","year":"2010","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.002_bib0115","first-page":"887","article-title":"Update on the clinical use of kinase inhibitors in melanoma","volume":"15","author":"Cosgarea","year":"2017","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"issue":"24","key":"10.1016\/j.critrevonc.2018.11.002_bib0125","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res."},{"issue":"6892","key":"10.1016\/j.critrevonc.2018.11.002_bib0130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","article-title":"Second- and third-generation drugs for immuno-oncology treatment-The more the better?","volume":"74","author":"Dempke","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0140","series-title":"32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017); November 07","article-title":"Preliminary safety, efficacy and biomarker results from the phase 1\/2 study of CD\u2010122\u2010biased agonist NKTR\u2010214 plus nivolumab in patients with locally advanced\/metastatic solid tumors","author":"Diab","year":"2017"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2018.11.002_bib0145","article-title":"1187PA phase 1\/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma","volume":"28","author":"Diab","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.002_bib0150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.002_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109080","article-title":"Lymphocyte activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo","volume":"9","author":"Durham","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0160","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.002_bib0165","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","article-title":"Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity","volume":"61","author":"Fisher","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.002_bib0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.002_bib0175","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2018.11.002_bib0180","article-title":"Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase 1 results from ECHO-202\/KEYNOTE-037 [abstract]","volume":"27","author":"Gangadhar","year":"2016","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.002_bib0190","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.002_bib0195","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.002_bib0200","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s10637-014-0066-9","article-title":"Phase II trial of vorinostat in advanced melanoma","volume":"32","author":"Haas","year":"2014","journal-title":"Invest. New. Drugs"},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0205","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1200\/jco.2013.31.15_suppl.9010","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) [abstract]","volume":"31","author":"Hamid","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"9839","key":"10.1016\/j.critrevonc.2018.11.002_bib0210","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.002_bib0215","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2018.11.002_bib0220","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.002_bib0225","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.002_bib0230","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4161\/cc.11.2.18707","article-title":"The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells","volume":"11","author":"Hou","year":"2012","journal-title":"Cell. Cycle (Georget., Tex.)."},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2018.11.002_bib0235","article-title":"Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma [abstract]","volume":"27","author":"Hwu","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl._6","key":"10.1016\/j.critrevonc.2018.11.002_bib0240","article-title":"Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma","volume":"27","author":"Hwu","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0245","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1200\/jco.2013.31.15_suppl.3026","article-title":"A phase I study of indoximod in combination with docetaxel in metastatic solid tumors [abstract]","volume":"31","author":"Jackson","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.002_bib0250","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.critrevonc.2018.11.002_bib0255","doi-asserted-by":"crossref","first-page":"37762","DOI":"10.18632\/oncotarget.9326","article-title":"The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.002_bib0260","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0265","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.002_bib0270","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-1161-03","article-title":"T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma","volume":"10","author":"Ladanyi","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0275","article-title":"Epacadostat plus pembrolizumab in patients with advanced RCC: preliminary phase I\/II results from ECHO-202\/KEYNOTE-037","volume":"35","author":"Lara","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2018.11.002_bib0280","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2018.11.002_bib0290","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0295","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1200\/jco.2015.33.15_suppl.9006","article-title":"Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma [abstract]","volume":"33","author":"Larkin","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0300","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.002_bib0305","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/1078-0432.CCR-15-1212","article-title":"Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients\u2013report of a phase I\/IIa clinical trial","volume":"22","author":"Legat","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0310","article-title":"Phase 1b\/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 na\u00efve & experienced metastatic melanoma patients","volume":"35","author":"Leung","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2018.11.002_bib0315","first-page":"P232","article-title":"Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies [abstract]","volume":"4","author":"Lipson","year":"2016","journal-title":"J Immunother. Cancer."},{"issue":"9992","key":"10.1016\/j.critrevonc.2018.11.002_bib0320","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2018.11.002_bib0325","doi-asserted-by":"crossref","first-page":"P181","DOI":"10.1186\/2051-1426-3-S2-P181","article-title":"A phase I\/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) [abstract]","volume":"3","author":"Long","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0330","series-title":"A Phase I\/III, Multicenter, Open-Label Trial of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab for the Treatment of Unresected, Stage IIIb-IV Melanoma (MASTERKEY-265)","author":"Long","year":"2015"},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.002_bib0335","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/annonc\/mdw265","article-title":"Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study","volume":"27","author":"Long","year":"2016","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.11.002_bib0340","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0345","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2016.34.15_suppl.9506","article-title":"Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort [abstract]","volume":"34","author":"Long","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0350","series-title":"Pembrolizumab (Pembro) Plus Ipilimumab (Ipi) for Advanced Melanoma: Results of the KEYNOTE-029 Expansion Cohort","author":"Long","year":"2016"},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.002_bib0355","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.002_bib0360","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bjc.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Loskog","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0365","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1074\/jbc.M109.068668","article-title":"Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1","volume":"285","author":"Maddodi","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0370","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","article-title":"A phase II study of REOLYSIN((R)) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","volume":"79","author":"Mahalingam","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.002_bib0375","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.002_bib0380","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2018.11.002_bib0385","first-page":"5","article-title":"Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies [abstract]","volume":"4","author":"Massarelli","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl. 19","key":"10.1016\/j.critrevonc.2018.11.002_bib0390","article-title":"Abstract 5023: synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1\/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy [abstract]","volume":"74","author":"Mautino","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.002_bib0395","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0400","article-title":"A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and\/or metastatic solid tumors and relapsed\/refractory B-cell non-hodgkin\u2019s lymphoma (B-NHL) [abstract]","volume":"31","author":"Melero","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0405","article-title":"Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma","author":"Milhem","year":"2018","journal-title":"AACR Annual Meeting 2018; April 14\u201318"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0410","first-page":"1507","article-title":"Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms","volume":"5","author":"Monsma","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0415","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.002_bib0420","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00262-017-2030-y","article-title":"A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma","volume":"66","author":"Patel","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0425","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3747\/co.2007.97","article-title":"Single-agent interleukin-2 in the treatment of metastatic melanoma","volume":"14","author":"Petrella","year":"2007","journal-title":"Curr. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2018.11.002_bib0430","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2018.11.002_bib0435","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2018.11.002_bib0440","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0445","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/jco.2015.33.15_suppl.3003","article-title":"Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and\/or MEK (trametinib) inhibitors in advanced melanoma [abstract]","volume":"33","author":"Ribas","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.002_bib0450","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0455","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2016.34.15_suppl.3014","article-title":"Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: phase 1 KEYNOTE-022 study [abstract]","volume":"34","author":"Ribas","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2018.11.002_bib0460","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2018.11.002_bib0465","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. \u2009Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0470","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2018.11.002_bib0475","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0480","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2018.11.002_bib0485","first-page":"vi552","article-title":"Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma [abstract]","volume":"27","author":"Robert","year":"2016","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.11.002_bib0490","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1200\/JCO.2017.35.15_suppl.9504","article-title":"Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment [abstract]","volume":"35","author":"Robert","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0495","doi-asserted-by":"crossref","unstructured":"Robert C, Karaszewska B, Schachter J, et al., 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E\/K mutation-positive cutaneous melanoma. Eur. J. Cancer. 51:S663.","DOI":"10.1016\/S0959-8049(16)31820-2"},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0500","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3264217","article-title":"Advances in immunotherapy for melanoma: a comprehensive review","volume":"2017","author":"Rodriguez-Cerdeira","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0505","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1479-5876-12-97","article-title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial","volume":"12","author":"Romano","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0510","article-title":"Advanced melanoma: current treatment options, biomarkers, and future perspectives","author":"Rozeman","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.002_bib0515","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"Ruter","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.002_bib0520","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"10105","key":"10.1016\/j.critrevonc.2018.11.002_bib0525","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet (Lond., Engl.)"},{"issue":"17","key":"10.1016\/j.critrevonc.2018.11.002_bib0530","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of Long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.002_bib0535","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.coi.2011.12.011","article-title":"Modulation of GITR for cancer immunotherapy","volume":"24","author":"Schaer","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.002_bib0540","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0545","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.002_bib0550","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni759","article-title":"Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance","volume":"3","author":"Shimizu","year":"2002","journal-title":"Nat. Immunol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0555","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/jco.2012.30.15_suppl.2501","article-title":"A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies [abstract]","volume":"30","author":"Soliman","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0560","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/jco.2013.31.15_suppl.3069","article-title":"A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors [abstract]","volume":"31","author":"Soliman","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0565","article-title":"A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer [abstract]","volume":"32","author":"Soliman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.002_bib0570","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.002_bib0575","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2018.11.002_bib0580","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/1078-0432.CCR-14-3061","article-title":"Pembrolizumab for treatment of patients with advanced or unresectable melanoma","volume":"21","author":"Sullivan","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0585","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/jco.2015.33.15_suppl.9007","article-title":"A phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment [abstract]","volume":"33","author":"Sullivan","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2018.11.002_bib0590","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2017.35.15_suppl.3063","article-title":"Atezolizumab (A) + cobimetinib (C) + vemurafenib (v) in BRAFV600-mutant metastatic melanoma (mel): updated safety and clinical activity [abstract]","volume":"35","author":"Sullivan","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.002_bib0595","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2018.11.002_bib0600","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0605","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fimmu.2015.00034","article-title":"Tryptophan-degrading enzymes in tumoral immune resistance","volume":"6","author":"van Baren","year":"2015","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.critrevonc.2018.11.002_bib0610","doi-asserted-by":"crossref","first-page":"384","DOI":"10.21037\/atm.2017.09.09","article-title":"New trends in antitumor vaccines in melanoma","volume":"5","author":"Vasquez","year":"2017","journal-title":"An. Transl. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.002_bib0615","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.002_bib0620","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10637-012-9866-y","article-title":"A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma","volume":"31","author":"Wang-Gillam","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0625","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.seminoncol.2015.05.007","article-title":"Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy","volume":"42","author":"Wargo","year":"2015","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0630","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.002_bib0635","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.002_bib0640","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","article-title":"Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases","volume":"99","author":"Williams","year":"2017","journal-title":"Int. J Radiat. Oncol. Biol Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.002_bib0645","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.critrevonc.2018.11.002_bib0650","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.002_bib0655","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00280-014-2501-1","article-title":"Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)","volume":"74","author":"Xia","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.002_bib0660","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.hoc.2009.03.006","article-title":"The history and future of chemotherapy for melanoma","volume":"23","author":"Yang","year":"2009","journal-title":"Hematol Oncol. Clin. North. Am."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0665","first-page":"6","article-title":"Combined inhibition of the IDO and PD-1 pathways improves the response rate for patients with advanced melanoma","author":"Zakharia","year":"2017","journal-title":"Proceedings of the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference"},{"issue":"Suppl 5","key":"10.1016\/j.critrevonc.2018.11.002_bib0670","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nov218.21","article-title":"Imct-21updates on phase 1b\/2 combination study of the IDO pathway ihibitor indoximod with temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors","volume":"17","author":"Zakharia","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0675","series-title":"Updates on phase1b\/2 Trial of the Indoleamine 2,3-Dioxygenase Pathway (IDO) Inhibitor Indoximod Plus Checkpoint Inhibitors for the Treatment of Unresectable Stage 3 or 4 Melanoma","author":"Zakharia","year":"2016"},{"issue":"CT117","key":"10.1016\/j.critrevonc.2018.11.002_bib0680","article-title":"Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma","volume":"77","author":"Zakharia","year":"2017","journal-title":"Cancer Res."},{"issue":"51","key":"10.1016\/j.critrevonc.2018.11.002_bib0685","doi-asserted-by":"crossref","first-page":"89182","DOI":"10.18632\/oncotarget.21269","article-title":"Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study","volume":"8","author":"Zakharia","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0690","doi-asserted-by":"crossref","unstructured":"Zakharia Y, Drabick J, Khleif S, et al. 514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma. European Journal of Cancer.51:S108.","DOI":"10.1016\/S0959-8049(16)30315-X"},{"key":"10.1016\/j.critrevonc.2018.11.002_bib0695","first-page":"1","article-title":"TIM-3 and its regulatory role in immune responses","volume":"350","author":"Zhu","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:55:32Z","timestamp":1764863732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818301859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":139,"alternative-id":["S1040842818301859"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced stage melanoma therapies: Detailing the present and exploring the future","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}